Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun;31(6):3567-3568.
doi: 10.1245/s10434-024-15158-3. Epub 2024 Mar 8.

Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?

Lucas Goense  1 , Richard van Hillegersberg  2
Affiliations
Editorial

Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?

Lucas Goense et al. Ann Surg Oncol. 2024 Jun.
No abstract available

PubMed Disclaimer

References

    1. van der Zijden CJ, van der Sluis PC, Mostert B, Nuyttens JJME, Spaander VMCW, Valkema R, et al. Adjuvant therapy for patients with a tumor-positive resection margin after neoadjuvant chemoradiotherapy and esophagectomy. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14912-x - DOI - PubMed
    1. Raman V, Jawitz OK, Voigt SL, Yang CJ, D’Amico TA, Harpole DH Jr, et al. The role of adjuvant therapy in patients with margin-positive (R1) esophagectomy: a national analysis. J Surg Res. 2020;249:82–90. https://doi.org/10.1016/j.jss.2019.11.035 . - DOI - PubMed - PMC
    1. Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, Knight WRC, Baker CR, et al. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. Br J Surg. 2020;107:1801–10. - PubMed
    1. Raja S, Rice TW, Lu M, Semple ME, Blackstone EH, Murthy SC, et al. Adjuvant therapy after neoadjuvant therapy for esophageal cancer: who needs it? Ann Surg. 2023;278:e240–9. - DOI - PubMed
    1. Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022;28:3277–86. - DOI - PubMed - PMC

Publication types

Substances

LinkOut - more resources